Show simple item record

dc.contributor.authorChristodoulou, Marianna
dc.contributor.authorReeves, K
dc.contributor.authorHodgson, Clare
dc.contributor.authorZeniou, A
dc.contributor.authorSlevin, F
dc.contributor.authorKennedy, J
dc.contributor.authorHoskin, P
dc.contributor.authorHenry, A
dc.contributor.authorChoudhury, Ananya
dc.date.accessioned2018-06-30T14:11:11Z
dc.date.available2018-06-30T14:11:11Z
dc.date.issued2018-06-02
dc.identifier.citationOutcomes of radiosensitisation in elderly patients with advanced bladder cancer. 2018, Radiother Oncolen
dc.identifier.issn1879-0887
dc.identifier.pmid29871812
dc.identifier.doi10.1016/j.radonc.2018.05.022
dc.identifier.urihttp://hdl.handle.net/10541/621080
dc.description.abstractThere is little evidence to guide treatment in elderly patients with muscle invasive bladder cancer (MIBC). We evaluated the efficacy and tolerability of concurrent radical radiotherapy with gemcitabine radiosensitisation (GemX) in elderly patients with MIBC and compared outcomes to those from the bladder carbogen and nicotinamide (BCON) phase III trial.
dc.language.isoenen
dc.rightsArchived with thanks to Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncologyen
dc.titleOutcomes of radiosensitisation in elderly patients with advanced bladder cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, United Kingdomen
dc.identifier.journalRadiotherapy and Oncologyen
html.description.abstractThere is little evidence to guide treatment in elderly patients with muscle invasive bladder cancer (MIBC). We evaluated the efficacy and tolerability of concurrent radical radiotherapy with gemcitabine radiosensitisation (GemX) in elderly patients with MIBC and compared outcomes to those from the bladder carbogen and nicotinamide (BCON) phase III trial.


Files in this item

This item appears in the following Collection(s)

Show simple item record